➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Baxter
Johnson and Johnson
Medtronic
Harvard Business School

Last Updated: October 23, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,089,489

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,089,489
Title:Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Abstract: A dual release oral dosage system/dosage form comprising an immediate release component/composition and a delayed release component/composition is described. Each of the immediate release component/composition and delayed release component/composition comprises one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and/or a salt of the metabolite. The dual release oral dosage system/dosage form exhibits an improved pharmacokinetic profile relative to the current Diclectin.RTM. formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting in pregnancy (NVP).
Inventor(s): Vranderick; Manon (St-Lazare, CA), St-Onge; Jean-Luc (Mirabel, CA), Gedeon; Christelle (Toronto, CA), Gallo; Michele (Blainville, CA), Gervais; Eric (Blainville, CA)
Assignee: Duchesnay Inc. (Blainville, CA)
Application Number:14/228,228
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,089,489
Patent Claims: 1. A dual release oral dosage form comprising: (A) an immediate release composition comprising: (a) from about 5 mg to about 20 mg of doxylamine and/or a pharmaceutically acceptable salt thereof; and (b) from about 5 mg to about 20 mg of pyridoxine and/or a pharmaceutically acceptable salt thereof; and (B) a delayed release composition comprising: (a) from about 5 mg to about 20 mg of doxylamine and/or a pharmaceutically acceptable salt thereof; and (b) from about 5 mg to about 20 mg of pyridoxine and/or a pharmaceutically acceptable salt thereof; wherein said immediate release composition is for effecting release of (a) doxylamine and/or pharmaceutically acceptable salt thereof and (b) pyridoxine and/or pharmaceutically acceptable salt thereof, which begins prior to release of (a) doxylamine and/or pharmaceutically acceptable salt thereof and (b) pyridoxine and/or pharmaceutically acceptable salt thereof, from the delayed release component, within the gastrointestinal tract.

2. The dual release oral dosage form of claim 1, wherein said immediate release composition is for effecting release substantially within the stomach.

3. The dual release oral dosage form of claim 1, wherein said delayed release composition is for effecting release substantially within the intestine, and there is substantially no release from said delayed release composition in the stomach.

4. The dual release oral dosage form of claim 1, wherein said dosage form comprises from about 10 mg to about 20 mg of doxylamine and/or pharmaceutically acceptable salt thereof.

5. The dual release oral dosage form of claim 4, wherein said dosage form comprises about 20 mg of doxylamine and/or pharmaceutically acceptable salt thereof.

6. The dual release oral dosage form of claim 1, wherein said dosage form comprises from about 10 mg to about 25 mg of pyridoxine and/or pharmaceutically acceptable salt thereof.

7. The dual release oral dosage form of claim 6, wherein said dosage form comprises from about 10 mg to about 20 mg of pyridoxine and/or pharmaceutically acceptable salt thereof.

8. The dual release oral dosage form of claim 7, wherein said dosage form comprises about 20 mg of pyridoxine and/or pharmaceutically acceptable salt thereof.

9. The dual release oral dosage form of claim 1, wherein said dosage form comprises an identifying characteristic for correlation with its administration in a dosage regimen.

10. The dual release oral dosage form of claim 9, where said identifying characteristic is shape, color, an identifying mark, or any combination thereof.

11. The dual release oral dosage form of claim 1, wherein said dual release oral dosage form comprises (a) a core comprising said delayed release composition and (b) one or more coats substantially surrounding said core, said one or more coats comprising said immediate release composition.

12. The dual release oral dosage form of claim 11, wherein said core is coated with an enteric material.

13. The dual release oral dosage form of claim 1, wherein said immediate release composition is not in contact with said delayed release composition, within said dual release oral dosage form.

14. The dual release oral dosage form of claim 1, wherein said immediate release composition, delayed release composition, or both, further comprise at least one pharmaceutically acceptable carrier or excipient.

15. The dual release oral dosage form of claim 1, where said immediate release composition comprises a pharmaceutically acceptable doxylamine salt and a pharmaceutically acceptable pyridoxine salt.

16. The dual release oral dosage form of claim 1, wherein said delayed release composition comprises a pharmaceutically acceptable doxylamine salt and a pharmaceutically acceptable pyridoxine salt.

17. The dual release oral dosage form of claim 1, where said dual release oral dosage form is a tablet.

18. The dual release oral dosage form of claim 1, wherein the amount of doxylamine and/or pharmaceutically acceptable salt thereof comprised in the immediate release component or composition is substantially equivalent to the amount of doxylamine and/or pharmaceutically acceptable salt thereof comprised in the delayed release component or composition.

19. The dual release oral dosage form of claim 1, wherein the amount of pyridoxine and/or pharmaceutically acceptable salt thereof comprised in the immediate release component or composition is substantially equivalent to the amount of pyridoxine and/or pharmaceutically acceptable salt thereof comprised in the delayed release component or composition.

20. The dual release oral dosage form of claim 1, wherein said pharmaceutically acceptable doxylamine salt is doxylamine succinate.

21. The dual release oral dosage form of claim 1, wherein said pharmaceutically acceptable pyridoxine salt is pyridoxine hydrochloride.

22. The dual release oral dosage form of claim 1, wherein said immediate release composition comprises about 10 mg of doxylamine succinate and about 10 mg of pyridoxine hydrochloride, and said delayed release composition comprises about 10 mg of doxylamine succinate and about 10 mg of pyridoxine hydrochloride.

23. A method for alleviating the symptoms of nausea and vomiting in a mammal, said method comprising administering the dual release oral dosage form of claim 1 to a mammal in need thereof.

24. A method for alleviating the symptoms of nausea and vomiting of human pregnancy, said method comprising administering dual release oral dosage form of claim 1 to a pregnant human female in need thereof.

25. The method of claim 23, wherein said dual release oral dosage form is administered under fasted conditions.

26. The method of claim 24, wherein said dual release oral dosage form is administered under fasted conditions.

27. The method of claim 23, wherein said dual release oral dosage form is administered under fed conditions.

28. The method of claim 24, wherein said dual release oral dosage form is administered under fed conditions.

29. The method of claim 23, wherein said dual release oral dosage form is administered twice-a-day.

30. The method of claim 24, wherein said dual release oral dosage form is administered twice-a-day.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Harvard Business School
Colorcon
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.